References
- 1. Kim J. Unravelling the genomic landscape of leukemia using NGS techniques: the challenge remains. Blood Res. 2017 Dec;52(4):237-39. DOI: 10.5045/br.2017.52.4.23710.5045/br.2017.52.4.237
- 2. Bănescu C, Iancu M, Trifa AP, Dobreanu M, Moldovan VG, Duicu C, et al. Influence of XPC, XPD, XPF, and XPG gene polymorphisms on the risk and the outcome of acute myeloid leukemia in a Romanian population. Tumour Biol. 2016 Jul;37(7):9357-66. DOI: 10.1007/s13277-016-4815-610.1007/s13277-016-4815-6
- 3. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405. DOI: 10.1182/blood-2016-03-64354410.1182/blood-2016-03-643544
- 4. Coriu D, Jardan D, Jardan C, Tălmaci R, Dragomir M, Coliţă A. A new assay to identify recurrent mutations in acute myeloid leukemia using next-generation sequencing. Rev Romana Med Lab. 2014;22(1):93-9. DOI: 10.2478/rrlm-2014-000310.2478/rrlm-2014-0003
- 5. Cîrstea M, Coliță A, Ionescu B, Ghiaur A, Vasilescu D, Dobrea C, et al. Therapy-related myelodysplastic syndrome after successful treatment of acute promyelocytic leukemia: case report and literature review. Rev Romana Med Lab. 2017;25(2):165-79. DOI: 10.1515/rrlm-2017-001310.1515/rrlm-2017-0013
- 6. Kumar D, Mehta A, Panigrahi MK, Nath S, Saikia KK. DNMT3A (R882) mutation features and prognostic effect in acute myeloid leukemia in Coexistent with NPM1 and FLT3 mutations. Hematol Oncol Stem Cell Ther. 2018 Jun;11(2):82-9. DOI: 10.1016/j.hemonc.2017.09.00410.1016/j.hemonc.2017.09.004
- 7. Tang S, Shen H, Mao X, Dai H, Zhu X, Xue S, et al. FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2017 Oct;106(4):552-61. DOI: 10.1007/s12185-017-2256-710.1007/s12185-017-2256-7
- 8. Papaemmanuil E, Döhner H, Campbell PJ. Genomic Classification in Acute Myeloid Leukemia. N Engl J Med. 2016 Sep 1;375(9):900-1. DOI: 10.1056/NEJMc160873910.1056/NEJMc1608739
- 9. Roloff GW, Griffiths EA. When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter. Blood Adv. 2018 Nov 13;2(21):3070-80. DOI: 10.1182/bloodadvances.201802020610.1182/bloodadvances.2018020206
- 10. Antohe I, Dăscălescu A, Dănăilă C, Zlei M, Ivanov I, Sireteanu A, et al. FLT-3 ITD Positive Acute Basophilic Leukemia with Rare Complex Karyotype Presenting with Acute Respiratory Failure: Case Report. Rev Romana Med Lab. 2018;26(1):87-94. DOI: 10.1515/rrlm-2017-0036
- 11. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017 Jan 26;129(4):424-47. DOI: 10.1182/blood-2016-08-73319610.1182/blood-2016-08-733196
- 12. Patnaik MM. The importance of FLT3 mutational analysis in acute myeloid leukemia. Leuk Lymphoma. 2018 Oct;59(10):2273-86. DOI: 10.1080/10428194.2017.1399312
- 13. Bănescu C, Iancu M, Trifa AP, Cândea M, Benedek Lazar E, Moldovan VG, et al. From Six Gene Polymorphisms of the Antioxidant System, Only GPX Pro198Leu and GSTP1 Ile105Val Modulate the Risk of Acute Myeloid Leukemia. Oxid Med Cell Longev. 2016;2016:2536705. DOI: 10.1155/2016/253670510.1155/2016/2536705
- 14. El-Gammal MM, Ebid GT, Madney YM, Abo-Elazm OM, Kelany AK, Torra OS, et al. Clinical effect of combined mutations in DNMT3A, FLT3-ITD and NPM1 among Egyptian acute myeloid leukemia patients. Clin Lymphoma Myeloma Leuk. 2019 Available online 14 February 2019. pii: S2152-2650(19)30007-2, DOI: 10.1016/j.clml.2019.02.00110.1016/j.clml.2019.02.001
- 15. Oltean A, Chincesan MI, Marginean O, Horvath E. Myelodysplastic syndrome with myelofibrosis in a 12-year-old patient - A case report. Rev Romana Med Lab. 2018;26(1):95-103. DOI: 10.1515/rrlm-2017-003410.1515/rrlm-2017-0034
- 16. Patel SS, Kuo FC, Gibson CJ, Steensma DP, Soiffer RJ, Alyea EP et al. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 Jun 21;131(25):2816-25. DOI: 10.1182/blood-2018-01-82846710.1182/blood-2018-01-828467
- 17. Kunchala P, Kuravi S, Jensen R, McGuirk J, Balusu R. When the good go bad: Mutant NPM1 in acute myeloid leukemia. Blood Rev. 2018 May;32(3):167-83. DOI: 10.1016/j.blre.2017.11.00110.1016/j.blre.2017.11.001
- 18. Moarii M, Papaemmanuil E. Classification and risk assessment in AML: integrating cytogenetics and molecular profiling. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):37-44.
- 19. Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016 Jan 7;127(1):29-41. DOI: 10.1182/blood-2015-07-60449610.1182/blood-2015-07-604496
- 20. Blau O, Behrenbeck F, Bayanova M, Blau I, Bullinger L. Characteristics of DNMT3A-R882 Mutation in AML. Blood, 2018, 132(Suppl 1):5263.
- 21. Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019 Feb 14;133(7):676-87. DOI: 10.1182/blood-2018-08-86900810.1182/blood-2018-08-869008
- 22. Ardestani MT, Kazemi A, Chahardouli B, Mohammadi S, Nikbakht M, Rostami S, et al. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study. Turk J Haematol. 2018 Aug 3;35(3):158-67.
- 23. Tripon F, Crauciuc GA, Moldovan VG, Boglis A, Benedek I Jr, Lazar E, et al. Simultaneously FLT3, NPM1 and DNMT3A mutations in adult patients with acute myeloid leukemia-case study. Rev Romana Med Lab. 2019, in press, DOI: 10.2478/rrlm-2019-0022.10.2478/rrlm-2019-0022